Valeant Licenses Rights to AstraZeneca’s Troubled Psoriasis Drug Brodalumab
By Heather Cartwright & Shruti Desai; Heather Cartwright & Shruti Desai
Pharma Deals Review: Vol 2015 Issue 9 (Table of Contents)
Published: 26 Sep-2015
DOI: 10.3833/pdr.v2015.i9.2122 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In what can only be regarded as a risky move, Valeant Pharmaceuticals International has licensed development and commercialisation rights to AstraZeneca's IL-17 (interleukin-17) receptor monoclonal antibodybrodalumab, which is expected to be filed for regulatory approval in moderate-to-severe psoriasis in the EU and the US inQ4 2015...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS